[1] |
Sauvanet A. Surgical complications of pancreatectomy[J]. J Chir, 2008, 145(2):103-114.
|
[2] |
林青, 余敏, 陈汝福. 胰腺良性及低度恶性肿瘤的外科治疗[J]. 肝胆外科杂志, 2021, 29(6):405-407.
|
[3] |
Xu J, Li F, Zhan H, et al. Laparoscopic enucleation of pancreatic tumours: a single-institution experience of 66 cases[J]. ANZ J Surg, 2021, 91(1/2):106-110.
|
[4] |
张磊, 楼文晖. 重视胰腺切除术后远期并发症的诊治[J]. 中华外科杂志, 2022, 60(7):655-659.
|
[5] |
Lermite E, Sommacale D, Piardi T, et al. Complications after pancreatic resection: diagnosis, prevention and management[J]. Clin Res Hepatol Gastroenterol, 2013, 37(3):230-239.
|
[6] |
Cioffi JL, McDuffie LA, Roch AM, et al. Pancreaticojejunostomy stricture after pancreatoduodenectomy: outcomes after operative revision[J]. J Gastrointest Surg, 2016, 20(2):293-299.
|
[7] |
Yu X, Li H, Jin C, et al. Splenic vessel preservation versus Warshaw's technique during spleen-preserving distal pancreatectomy: a meta-analysis and systematic review[J]. Langenbecks Arch Surg, 2015, 400(2):183-191.
|
[8] |
Jiang Y, Jin JB, Zhan Q, et al. Robot-assisted duodenum-preserving pancreatic head resection with pancreaticogastrostomy for benign or premalignant pancreatic head lesions: a single-centre experience[J]. Int J Med Robot, 2018, 14(4):e1903.
|
[9] |
Chakraborty RK, Burns B. Systemic inflammatory response syndrome[M]. Treasure Island (FL): StatPearls Publishing, 2024.
|
[10] |
Trauner M, Fickert P, Stauber RE. Inflammation-induced cholestasis[J]. J Gastroenterol Hepatol, 1999, 14(10):946-959.
|
[11] |
Maatman TK, Butler JR, Quigley SN, et al. Leukocytosis after distal pancreatectomy and splenectomy as a marker of major complication[J]. Am J Surg, 2020, 220(2):354-358.
|
[12] |
沈红波, 傅德良, 蒋永剑, 等. 胰腺切除术后常见并发症的临床因素分析[J]. 外科理论与实践, 2012, 17(5):481-485.
|
[13] |
Kim SH, Hwang HK, Lee WJ, et al. Comprehensive complication index or clavien-dindo classification: which is better for evaluating the severity of postoperative complications following pancreatectomy?[J]. World J Surg, 2021, 45(3):849-856.
|
[14] |
Schroeder SM. Perioperative management of the patient with diabetes mellitus: update and overview[J]. Clin Podiatr Med Surg, 2014, 31(1):1-10.
|
[15] |
Tan DJH, Yaow CYL, Mok HT, et al. The influence of diabetes on postoperative complications following colorectal surgery[J]. Tech Coloproctol, 2021, 25(3):267-278.
|
[16] |
傅红兴, 许昌, 田阳, 等. 全胰腺切除联合自体胰岛移植治疗儿童慢性胰腺炎疗效[J/OL]. 中华肝脏外科手术学电子杂志, 2022, 11(2):118-122.
|
[17] |
Yuan S, Gill D, Giovannucci EL, et al. Obesity, type 2 diabetes, lifestyle factors, and risk of gallstone disease: a Mendelian randomization investigation[J]. Clin Gastroenterol Hepatol, 2022, 20(3):e529-537.
|
[18] |
Alghamdi AA, Jawas AM, Hart RS. Use of octreotide for the prevention of pancreatic fistula after elective pancreatic surgery: a systematic review and meta-analysis[J]. Can J Surg, 2007, 50(6):459-466.
|
[19] |
李永杰, 周耿, 方孟园, 等. 肝功能指标在诊断胆囊结石合并无症状胆总管结石中的作用[J]. 中华肝胆外科杂志, 2014, 20(6):431-434.
|
[20] |
李华, 李光明, 胡坚方, 等. 急性胆汁淤积诱导大鼠肝细胞损伤的机制研究[J]. 实用医学杂志, 2009, 25(5):700-702.
|
[21] |
Donati A, Ruzzi M, Adrario E, et al. A new and feasible model for predicting operative risk[J]. Br J Anaesth, 2004, 93(3):393-399.
|
[22] |
Schorn S, Vogel T, Demir IE, et al. Do somatostatin-analogues have the same impact on postoperative morbidity and pancreatic fistula in patients after pancreaticoduodenectomy and distal pancreatectomy? -asystematic review with meta-analysis of randomized-controlled trials[J]. Pancreatology, 2020, 20(8):1770-1778.
|
[23] |
Fazel A, Li SC, Burton FR. Octreotide relaxes the hypertensive sphincter of Oddi: pathophysiological and therapeutic implications[J]. Am J Gastroenterol, 2002, 97(3):612-616.
|
[24] |
Velõsy B, Madácsy L, Szepes A, et al. The effects of somatostatin and octreotide on the human sphincter of Oddi[J]. Eur J Gastroenterol Hepatol, 1999, 11(8):897-901.
|
[25] |
Han ZH, He ZM, Chen WH, et al. Octreotide-induced acute life-threatening gallstones after vicarious contrast medium excretion: a case report[J]. World J Clin Cases, 2021, 9(25):7484-7489.
|
[26] |
Brighi N, Lamberti G, Maggio I, et al. Biliary stone disease in patients receiving somatostatin analogs for neuroendocrine neoplasms. a retrospective observational study[J]. Dig Liver Dis, 2019, 51(5):689-694.
|
[27] |
Brighi N, Panzuto F, Modica R, et al. Biliary stone disease in patients with neuroendocrine tumors treated with somatostatin analogs: a multicenter study[J]. Oncologist, 2020, 25(3):259-265.
|
[28] |
Hussaini SH, Pereira SP, Murphy GM, et al. Composition of gall bladder stones associated with octreotide: response to oral ursodeoxycholic acid[J]. Gut, 1995, 36(1):126-132.
|
[29] |
于汉卿, 王培林. 3125例体检者年龄、性别与胆囊结石发病率的分析[J]. 世界最新医学信息文摘, 2015, 15(9):128-129.
|